Literature DB >> 7826122

Anthracyclines: cardiotoxicity and its prevention.

J P Hale1, I J Lewis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7826122      PMCID： PMC1030067          DOI： 10.1136/adc.71.5.457

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  50 in total

1.  DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.

Authors:  A Bodley; L F Liu; M Israel; R Seshadri; Y Koseki; F C Giuliani; S Kirschenbaum; R Silber; M Potmesil
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

2.  Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study.

Authors:  J Treat; A Greenspan; D Forst; J A Sanchez; V J Ferrans; L A Potkul; P V Woolley; A Rahman
Journal:  J Natl Cancer Inst       Date:  1990-11-07       Impact factor: 13.506

3.  Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer.

Authors:  A M Goorin; A R Chauvenet; A R Perez-Atayde; J Cruz; R McKone; S E Lipshultz
Journal:  J Pediatr       Date:  1990-01       Impact factor: 4.406

4.  Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling.

Authors:  G Hausdorf; G Morf; G Beron; R Erttmann; K Winkler; G Landbeck; E W Keck
Journal:  Br Heart J       Date:  1988-10

Review 5.  Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity.

Authors:  H G Keizer; H M Pinedo; G J Schuurhuis; H Joenje
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

6.  Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study.

Authors:  A Gabizon; T Peretz; A Sulkes; S Amselem; R Ben-Yosef; N Ben-Baruch; R Catane; S Biran; Y Barenholz
Journal:  Eur J Cancer Clin Oncol       Date:  1989-12

7.  Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) in human leukemic HL-60 cells.

Authors:  E Monti; B K Sinha
Journal:  Cancer Commun       Date:  1990

Review 8.  Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy.

Authors:  S S Bielack; R Erttmann; K Winkler; G Landbeck
Journal:  Eur J Cancer Clin Oncol       Date:  1989-05

9.  Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation.

Authors:  J Shapira; M Gotfried; M Lishner; M Ravid
Journal:  Cancer       Date:  1990-02-15       Impact factor: 6.860

10.  Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics.

Authors:  B Marchandise; E Schroeder; A Bosly; C Doyen; P Weynants; R Kremer; H Pouleur
Journal:  Am Heart J       Date:  1989-07       Impact factor: 4.749
View more
  10 in total

1.  Fluorescence spectra of cardiac myosin and in vivo experiment: studies on daunorubicin-induced cardiotoxicity.

Authors:  Yang Liu; Chi Chen; Xiaoxiang Duan; Wenting Ma; Man Wang; Mengyi Tu; Ying Chen
Journal:  Iran J Basic Med Sci       Date:  2015-12       Impact factor: 2.699

Review 2.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

3.  Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma.

Authors:  Raimund Waldner; Claudia Laschan; Alfred Lohninger; Martin Gessner; Heinz Tüchler; Marlies Huemer; Wolfgang Spiegel; Heidrun Karlic
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-08       Impact factor: 4.553

4.  Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma.

Authors:  D S Richardson; S M Kelsey; S A Johnson; M Tighe; J D Cavenagh; A C Newland
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Fasting and cancer treatment in humans: A case series report.

Authors:  Fernando M Safdie; Tanya Dorff; David Quinn; Luigi Fontana; Min Wei; Changhan Lee; Pinchas Cohen; Valter D Longo
Journal:  Aging (Albany NY)       Date:  2009-12-31       Impact factor: 5.682

Review 6.  Preparation and Evaluation of Animal Models of Cardiotoxicity in Antineoplastic Therapy.

Authors:  Chenchen Meng; Lu Fan; Xiaoming Wang; Yunjiao Wang; Yanyang Li; Shuchao Pang; Shichao Lv; Junping Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-07-05       Impact factor: 7.310

7.  Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.

Authors:  Thulani H Senanayake; Galya Warren; Xin Wei; Serguei V Vinogradov
Journal:  J Control Release       Date:  2013-02-04       Impact factor: 9.776

8.  Imaging doxorubicin and polymer-drug conjugates of doxorubicin-induced cardiotoxicity with bispecific anti-myosin-anti-DTPA antibody and Tc-99m-labeled polymers.

Authors:  Rajiv Panwar; Prashant Bhattarai; Vishwesh Patil; Keyur Gada; Stan Majewski; Ban An Khaw
Journal:  J Nucl Cardiol       Date:  2018-02-01       Impact factor: 5.952

9.  Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study.

Authors:  Yasmin Hamirani; Ibrahim Fanous; Christopher M Kramer; Andrew Wong; Michael Salerno; Patrick Dillon
Journal:  Med Oncol       Date:  2016-06-22       Impact factor: 3.064

Review 10.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.